References
1. Li C, Ming-Chia Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 2013, 25:210–216
2. Vuorinen-Markkola H Hyperuricemia and insulin resistance J Clin Endocrinol Merab 1994; 78: 25-29.
3. Corry DB, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. Journal of hypertension. 2008;26:269–275.
4. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology : JASN. 2005;16:3553–3562.
5. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. The Journal of clinical investigation. 1977;60:999–1007.
6. Nakagawa T, et al. Uric acid a uremic toxin? Blood purification. 2006;24:67–70.
7. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal Curr Hypertens Rep. 2013 Jun; 15(3): 175–181
8. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. Journal of molecular evolution. 1992;34:78–84.
9. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Molecular biology and evolution. 2002;19:640–653.
10. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. British medical journal. 1973;1:449–451.
11. Johnson RJ, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–1190.
12. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131–139.
13. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol-Cell Ph. 2007;293:C584–C596.
14. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–480.
15. Nakanishi N, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–530.
16. Sundstrom J, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.
17. De Leeuw PW, et al. Prognostic significance of renal function in elderly patients with isolated Systolic hypertension: Results from the Syst-eur trial. Journal of the American Society of Nephrology. 2002;13 Doi 10.1097/01.Asn.0000027871.86296.92.
18. Bickel C, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12–17.
19. Kanbay M, Jensen T, Solak Y, Myphuon L, Roncal-Jimenez C, Rivard Ch, Lanaspa MA, Nakagawa T Johnson RJ. Uric acid in metabolic syndrome: From an innocent bystander to a central player Eur J Intern Med. 2016 Apr; 29: 3–8
20. Afzali A, Weiss NS, Boyko EJ, Ioannu GN. Association between serum uric acid level and chronic liver disease in the United States Hepatology 2010; 52: 578-589
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21
22. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: A cross-sectional study. J Hepatol. 2009;50:1029–1034
23. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease Aliment Pharmacol Ther 2011;34:757-66.
24. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013;62:392–399
25. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: Potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287:40732–40744
26. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol 2012; 57 :642–654
27. Iracheta-Vellve A, Petrasek J, Satishchandran A, Gyongyosi B, Saha B, Kodys K, Fitzgerald KA, Kurt-Jones EA, Szabo G. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol. 2015;63:1147–1155
28. Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K Szabo G. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat–cholesterol–sugar diet model in mice Journal of Translational Medicine 201513:193 https://doi.org/10.1186/s12967-015-0552-7
29. Mehal WZ. The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease Dig Dis 2014;32:507–515.
30. Friedman SL, Neushchwander-Tetri BA, Rinella M, Sanyal A. Mechanisms of NAFLD development and therapeutic strategies Nature Medicine 2018; 24:908-922
31. Huang Q, Yu J, Zhang X, Liu Sh, Ge Y. Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease. Biomed Rep 2016; 5: 188–192
32. Feig DI, Kang DH, Johnson RJ Uric acid and cardiovascular risk N Engl J Med. 2008 Oct 23; 359(17): 1811–1821.
33. Ampuero J, Gallego-Duran R, Romero-Gomez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: Meta-analysis. Rev Esp Enferm Dig 2015; 107: 10-16.
34. Seko Y, Yamaguchi K, Itoh Y, The genetic backgrounds in non-alcoholic fatty liver disease Clin J Gastroenterol 2018;11:97-102
35. Aller R, Laserna C, Rojo MÁ, Mora N, García Sánchez C, Pina M, Sigüenza R, Durà M, Primo D, Izaola O, de Luis D. Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease. Rev Esp Enferm Dig. 2018 Jul 23;110. doi: 10.17235/reed.2018.5602/2018. [Epub ahead of print]
36. Xu C. F., Yu C. H., Xu L., Sa X. Y., Li Y. M. Hypouricemic therapy. A novel potential therapeutic option for nonalcoholic fatty liver disease. Hepatology 2010 52, 1865–1866